(Q38430878)

3 September 2017

The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients (English)

1 reference

3 September 2017

Kristen N Ganjoo

1

1 reference

3 September 2017

Annette M Moore

2

1 reference

3 September 2017

Attilio Orazi

3

1 reference

3 September 2017

Joy A Sen

4

1 reference

3 September 2017

Cynthia S Johnson

5

1 reference

3 September 2017

Caroline S An

6

1 reference

3 September 2017

11 August 2007

1 reference

Journal of Cancer Research and Clinical Oncology

3 September 2017

1 reference

3 September 2017

134

1 reference

3 September 2017

3

1 reference

3 September 2017

381-387

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-007-0294-x

3 September 2017

0 references

cites work

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

12 December 2020

Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma

1 reference

12 December 2020

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

12 December 2020

Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes

1 reference

12 December 2020

Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Vascular endothelial growth factor: basic science and clinical progress

1 reference

12 December 2020

Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors

1 reference

12 December 2020

Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas.

1 reference

12 December 2020

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

1 reference

12 December 2020

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

1 reference

12 December 2020

Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors.

1 reference

12 December 2020

Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis

1 reference

12 December 2020

Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas

1 reference

12 December 2020

Lymphangiogenesis and tumor metastasis

1 reference

12 December 2020

Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.

1 reference

12 December 2020

Hyperplasia of lymphatic vessels in VEGF-C transgenic mice

1 reference

12 December 2020

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

12 December 2020

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

1 reference

12 December 2020

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

12 December 2020

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

1 reference

12 December 2020

The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma

1 reference

12 December 2020

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

12 December 2020

Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma

1 reference

12 December 2020

Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR

1 reference

12 December 2020

Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

Vascular endothelial growth factor C induces angiogenesis in vivo.

1 reference

12 December 2020

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C

1 reference

12 December 2020

Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia

1 reference

12 December 2020

10.1007/S00432-007-0294-X

Identifiers

DOI

1 reference

3 September 2017

1 reference